Navigation Links
Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
Date:6/5/2009

SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated disease and cancer, today announced that Glenn Rice, President and COO will present on Wednesday, June 10, at 11:30 a.m. ET at the 8th Annual Needham Life Sciences Conference taking place at the New York Palace Hotel.

There will be a live webcast of the presentation, which will be accessible through a link posted on the home page and investor relations section of the PCYC website. The webcast will be available for replay through June 26, 2009.

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commerci
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmacyclics Files Registration Statement for Rights Offering
2. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
4. Pharmacyclics Secures $5.0 Million in Debt Financing
5. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
7. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
8. Pharmacyclics Announces It Received Nasdaq Notification
9. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
10. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
11. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... July 31 InNexus,Biotechnology Inc., (TSX VENTURE: ... a drug development company commercializing the,next generation ... Cross Linking,(DXL(TM)) technology, will present at IBC,s ... of Innovative Therapeutics (DDT) Conference being,held in ...
... BERKELEY HEIGHTS, N.J., July 31 Genta,Incorporated (OTC ... release its second quarter 2008 financial results on ... conference call and live audio,webcast to discuss these ... Participants can access the live call by ...
... Amicus Therapeutics,(Nasdaq: FOLD ), a biopharmaceutical company ... of human,genetic diseases, will announce second quarter 2008 ... Thursday, August 7, 2008. The results,announcement will be ... that,afternoon at 5 p.m. EDT., Interested participants ...
Cached Biology Technology:InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 3Amicus Therapeutics Announces Second Quarter 2008 Results Release Date 2
(Date:7/11/2014)... American Society for Bone and Mineral Research awarded Michael ... Medicine (BUSM), with the 2014 Louis V. Avioli Award. ... BUSM, is internationally known for revolutionizing the understanding of ... , The award honors a member of the American ... contributions to bone and mineral basic research. It is ...
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... that remains unusually stable in the body, researchers at ... to the development of therapeutic RNA nanotechnology. Peixuan ... and professor of biomedical engineering, and his colleagues in ... construction of a thermodynamically stable RNA nanoparticle online in ...
... it turns out, suppresses melatonin 5 times more than exposure ... off an orange-yellow light. "Just as there are regulations and ... rules for the pollution stemming from artificial light at night," ... "White" light bulbs that emit light at shorter wavelengths ...
... Findings, published today in Nature and ... Pressure Genome-Wide Association Studies represent a major advance in our ... new potential therapeutic targets for prevention of heart disease and ... Research published in Nature and co-led by scientists ...
Cached Biology News:Team finds stable RNA nano-scaffold within virus core 2Dangers of exposure to 'white' light 2Dangers of exposure to 'white' light 3Discovery of blood pressure genes could help prevent cardiovascular disease 2Discovery of blood pressure genes could help prevent cardiovascular disease 3
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein...
NORMAL DONOR DONKEY SERUM...
... Molecular Probes Fc OxyBURST Green reagent (F-2902) ... of Boston University to permit measurement of ... and the subsequent oxidative burst directly in ... reagent consists of bovine serum albumin (BSA) ...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
Biology Products: